Skip to content
HowShorted

Fate Therapeutics, Inc. short interest in 2023

In 2023, Fate Therapeutics, Inc.'s disclosed short interest ran from 15.90% of shares outstanding on 13 Jan 2023 to 10.70% on 29 Dec 2023, a change of -5.20 percentage points. The year's high was 29.92% on 15 Jun 2023 and its low 10.70% on 29 Dec 2023, averaging 21.38% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.51 days on 14 Jul 2023. Full history: Fate Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fate Therapeutics, Inc. in 2023

2023 in figures

Start of year
15.90% (13 Jan 2023)
End of year
10.70% (29 Dec 2023)
Change
-5.20 pp
High
29.92% (15 Jun 2023)
Low
10.70% (29 Dec 2023)
Average
21.38%
Highest days to cover
19.51 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

Fate Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202315.90%1.62
31 Jan 202316.76%5.40
15 Feb 202317.34%7.31
28 Feb 202319.21%7.0210-K filed, results (8-K)
15 Mar 202322.21%7.72
31 Mar 202328.14%8.26
14 Apr 202327.70%8.94
28 Apr 202328.54%13.95
15 May 202329.61%11.1410-Q filed, results (8-K)
31 May 202329.59%14.89
15 Jun 202329.92%12.97
30 Jun 202326.36%7.89
14 Jul 202326.10%19.51
31 Jul 202328.09%15.29
15 Aug 202328.70%12.6010-Q filed, results (8-K)
31 Aug 202328.04%16.31
15 Sep 202324.64%5.90
29 Sep 202315.12%5.92
13 Oct 202314.00%10.72
31 Oct 202311.96%7.27
15 Nov 202311.78%4.9110-Q filed, results (8-K)
30 Nov 202311.88%7.94
15 Dec 202310.94%6.89
29 Dec 202310.70%5.26

See also: Fate Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.